Health
FDA approves new indication for drug to treat pediatric NDO patients – News-Medical.Net
Today, the U.S. Food and Drug Administration approved a new indication for Myrbetriq (mirabegron extended-release tablets) and Myrbetriq Granules (mirabegron for…
Today, the U.S. Food and Drug Administration approved a new indication for Myrbetriq (mirabegron extended-release tablets) and Myrbetriq Granules (mirabegron for extended-release oral suspension) to treat neurogenic detrusor overactivity (NDO), a bladder dysfunction related to neurological impairment, in children ages three years and older. Myrbetriq is also indicated for overactive bladder in adult patients.
Today’s action is a positive step for the treatment of NDO in young patients. Mirabegron,…
-
Business20 hours agoMacquarie tips 14% upside for this ASX tech stock
-
Noosa News16 hours agoWilliam Robinson dies aged 89
-
Business21 hours agoWhat to do with these 3 ASX 200 retail shares after strong price runs: experts
-
General16 hours agoCalls for corruption probe into completion of mayor’s Surfers Paradise Bowls Club site purchase